Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,447,761
  • Shares Outstanding, K 74,550
  • Annual Sales, $ 851,100 K
  • Annual Income, $ 4,600 K
  • 60-Month Beta 0.99
  • Price/Sales 1.71
  • Price/Cash Flow 8.40
  • Price/Book 1.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.05
  • Number of Estimates 4
  • High Estimate 0.00
  • Low Estimate -0.07
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -114.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.08 +1.78%
on 02/07/20
30.13 -35.55%
on 02/05/20
-9.88 (-33.72%)
since 01/14/20
3-Month
19.08 +1.78%
on 02/07/20
30.13 -35.55%
on 02/05/20
-5.09 (-20.77%)
since 11/14/19
52-Week
19.08 +1.78%
on 02/07/20
48.40 -59.88%
on 08/02/19
-11.49 (-37.17%)
since 02/14/19

Most Recent Stories

More News
Steer Clear Of These 5 Toxic Stocks Before It's Too Late

Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.

MYGN : 19.42 (-0.61%)
HLIT : 6.77 (-0.29%)
CSII : 44.25 (+2.01%)
MIME : 49.02 (+5.71%)
IAC : 237.95 (+1.04%)
Myriad Genetics (MYGN) Releases Favorable Prolaris Results

This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.

SYK : 221.54 (+1.90%)
RMD : 176.60 (+0.98%)
MYGN : 19.42 (-0.61%)
HRC : 109.47 (+0.77%)
New Study Demonstrates the Ability of Prolaris(R) to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the American Society of Clinical Oncology Genitouranary Cancer...

MYGN : 19.42 (-0.61%)
Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA

With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.

SYK : 221.54 (+1.90%)
RMD : 176.60 (+0.98%)
MYGN : 19.42 (-0.61%)
HRC : 109.47 (+0.77%)
Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global...

MYGN : 19.42 (-0.61%)
Myriad Submits sPMA for myChoice(R) CDx with Lynparza(R) in First-Line Maintenance Therapy in Advanced Ovarian Cancer

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and...

MYGN : 19.42 (-0.61%)
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN)

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Myriad Genetics, Inc., ("Myriad" or the "Company") (NASDAQ: MYGN) concerning whether the board breached...

MYGN : 19.42 (-0.61%)
Uber, AbbVie rise; Wynn, Myrian Genetics fall on Wall Street

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Friday:

UBER : 39.66 (-1.07%)
WYNN : 132.14 (-1.11%)
NOV : 22.89 (-1.93%)
SYNA : 81.36 (-0.11%)
MYGN : 19.42 (-0.61%)
SmarTrend Watching for Potential Rebound in Shares of Myriad Genetics After 29.33% Loss

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $19.08 to a high of $20.99. Yesterday, the shares fell 29.3%, which took the trading range below the 3-day low of...

MYGN : 19.42 (-0.61%)
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

ARAY : 3.52 (-2.76%)
SYK : 221.54 (+1.90%)
MYGN : 19.42 (-0.61%)
ABC : 94.36 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 20.33
1st Resistance Point 19.88
Last Price 19.42
1st Support Level 19.17
2nd Support Level 18.92

See More

52-Week High 48.40
Fibonacci 61.8% 37.20
Fibonacci 50% 33.74
Fibonacci 38.2% 30.28
Last Price 19.42
52-Week Low 19.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar